AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05159557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System
Description: Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
Study NCT05159557 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Limited In-Home Technology
Description: Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
Study NCT04971850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep study
Description: Procedures added by research during PSG :~* SDB screening questionnaires~* Electromyography (EMG) of accessory and abdominal muscles~* Cerebral oxygenation~* Mandibular movements~* Sleep headband (pre-teens and teens) or other connected device~* Automatic PSG analyzes~* Psychological and neuropsychological assessment The recordings of the study will be repeated at one year if the patient needs a treatment (surgery or noninvasive ventilation) following the results of the PSG.
Study NCT05019027 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and will be subsequently discontinued.~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol~* sotalol
Study NCT05457218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)
Study NCT05457218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IPC80
Description: The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)
Study NCT05457218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Buffalo Powder
Description: The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)
Study NCT06057324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based Apps
Description: Families which will use the digital interactive tools to empower parents in their daily dietary choices.
Study NCT06057324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-based diet toolkit and activities
Description: Families which will receive educational materials and adolescents will perform educational activities.
Study NCT06057324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy plant-based snacks
Description: Families in which children will include the snacks in their diet.
Study NCT06057324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based Apps + Mediterranean-based diet toolkit and activities
Description: Families which will use the digital interactive tools and receive educational material, and adolescents will perform educational activities.
Study NCT06057324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based Apps + Healthy plant-based snacks
Description: Families which will use the digital interactive tools and children will include the snacks in their diet.
Study NCT06057324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-based diet toolkit and activities + Healthy plant-based snacks
Description: Families which will receive educational material, adolescents will perform educational activities, and children will include the snacks in their diet.
Study NCT06388590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dragons
Description: The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.
Study NCT06388590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
Study NCT05947851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 5 and 20 mg tablets
Study NCT05947851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 10, 50, and 100 mg tablets
Study NCT05947851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: 10, 50, and 100 mg tablets
Study NCT05947851 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
Study NCT04773795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoZip System
Description: The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight.
Study NCT05582304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter
Study NCT05582304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: ACUVUE OASYS 1-Day with HydraLuxe Technology
Study NCT06553235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
Study NCT06553235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education
Description: - Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
Study NCT05177445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Prior to the beginning of the procedure the patient will be administered a nasal decongestant. Second to this, the patient will be advised to blow his/her nose. This step allows the physician a better view and allows the light exposure to reach the majority of the nasal mucosa(9).~To start the intervention the physician will introduce the phototherapy device inside the patient's nasal cavity as the patient sits in an upright condition. As the procedure is ongoing the physician will slightly rotate the device in order to minimize dryness and to irradiate all the nasal cavity. After the intervention the patient will be administered an emollient/moisturizing drug to further hydrate the nasal mucosa(9).~The intervention will have a crescent duration, the first one will be only two minutes and the following ones will increase 15 seconds each until a plateau is reached at 3 minutes in the 5th intervention.
Study NCT05177445 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: OT+Corticosteroids
Description: Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
Study NCT06491849 — intervention group
Intervention type: OTHER
Intervention: Peri-implant Condition Evaluation
Description: This intervention involves a detailed clinical evaluation of peri-implant conditions in patients who have received orthodontic mini implants. The assessments include measuring periodontal parameters such as probing depth, bleeding on probing, mucosal redness, plaque index, gingival index, and implant stability. The evaluations are conducted at specified intervals during and after orthodontic anchorage treatment to monitor changes and ensure the health of peri-implant tissues.
Study NCT05422339 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The MapHabit system
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study NCT05422339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MapHabit system
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study NCT05422339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The MapHabit system
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study NCT05163106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet
Description: Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
Study NCT05163106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
Study NCT04794894 — intervention group
Intervention type: BEHAVIORAL
Intervention: outpatient rehabilitation
Description: Treatment provided after completion of inpatient, acute rehabilitation.
Study NCT04859218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
Study NCT04859218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Description: two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
Study NCT05138432 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fruit and Vegetable Prescription Voucher
Description: Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
Study NCT04872101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study NCT04872101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study NCT06057324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based Apps + Mediterranean-based diet toolkit and activities + Healthy plant-based snacks
Description: Families which will use the digital interactive tools and will receive educational material, children will include the snacks in their diet, and adolescents will perform educational activities.
Study NCT05284799 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OVX836 480µg
Description: One single administration intramuscularly at Day 1
Study NCT05284799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 480µg
Description: One single administration intramuscularly at Day 1
Study NCT05284799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
Description: One single administration intramuscularly at Day 1
Study NCT05284799 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)
Description: One single administration intramuscularly at Day 1
Study NCT05284799 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single administration intramuscularly at Day 1
Study NCT05284799 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One single administration intramuscularly at Day 1
Study NCT06489782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 1
Description: Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
Study NCT06489782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Model 2
Description: Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
Study NCT04720911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person TASCS
Description: In-person clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
Study NCT04720911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth TASCS
Description: Telehealth clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
Study NCT04720911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered TASCS
Description: Self-administration of the intervention, including the Safety Planning Intervention, facilitated by the TASCS ED Patient App.
Study NCT04720911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up care
Description: Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
Study NCT04720911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up care
Description: Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
Study NCT06146088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 Vaccine
Description: Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
Study NCT05285384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
Study NCT06252532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct cortical stimulation (DCS) Alpha
Description: Rhythmic alpha stimulation
Study NCT06252532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct cortical stimulation (DCS) Theta
Description: Rhythmic theta stimulation applied
Study NCT06252532 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Direct cortical stimulation (DCS)
Description: Arrhythmic stimulation paradigm applied
Study NCT06252532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Direct cortical stimulation (DCS)
Description: Arrhythmic stimulation paradigm applied
Study NCT06252532 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct cortical stimulation (DCS) In-Phase Theta
Description: Rhythmic in-phase theta stimulation applied
Study NCT06252532 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct cortical stimulation (DCS) Anti-Phase Theta
Description: Rhythmic anti-phase theta stimulation applied
Study NCT06092892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery (BCS or mastectomy) with TAD/SNB
Description: Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
Study NCT06092892 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy
Description: Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
Study NCT06579053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone Tablets (Test)
Description: Take one test tablet each period
Study NCT06579053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone Tablets (Reference)
Description: Take one reference tablet each period
Study NCT05718843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study NCT03466424 — intervention group
Intervention type: RADIATION
Intervention: preoperative short-course radiotherapy
Description: Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
Study NCT04939545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacain
Description: Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.